Background {#Sec1}
==========

Pneumonia is a group of viral or bacterial infection-induced lung disorders that can cause the symptoms of fever, cough, shortness of breath and fatigue \[[@CR1]--[@CR3]\]. There are various types of pneumonia, such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), idiopathic interstitial pneumonia (IIP) \[[@CR4]--[@CR6]\]. Although the pathogenesis of pneumonia remains elusive, environmental exposure factors (e.g., tobacco smoking, virus or bacterial infection) and genetic variants may contribute to the susceptibility to pneumonia \[[@CR2], [@CR7], [@CR8]\]. Here, we investigated pneumonia-associated gene variations. After database retrieval and publication selection, we excluded reports of potential pneumonia-associated gene variation without enough or updated data, and finally focused on two variants, namely, *FCGR2A* rs1801274 and *MUC5B* rs35705950.

The human *FCGR2A* gene in the 1q23 chromosome region encodes a member of the heterogeneous Fc fragment of the IgG receptor family of immune receptors and contains a functional rs1801274 variation in exon 4, which leads to the amino acid alteration from histidine (H) to arginine (R) at position 131 of the FCGR2A protein \[[@CR9], [@CR10]\]. No prior meta-analysis regarding the genetic role of *FCGR2A* rs1801274 in pneumonia susceptibility has been reported, and studies have reported different findings \[[@CR11]--[@CR20]\]. Therefore, this is the first pooling analysis that has been conducted to assess the potential association between *FCGR2A* rs1801274 and overall pneumonia risk and was carried out according to PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines.

Human *MUC5B*, a gel-forming mucin gene in the 11p15.5 chromosome region \[[@CR21]\], can be expressed by certain bronchial epithelial cells and contains several variations (such as rs35705950) in a three kilobase region upstream of the *MUC5B* transcription start site \[[@CR22], [@CR23]\]. We found one meta-analysis published in 2013 \[[@CR24]\] and two meta-analyses published in 2015 \[[@CR25], [@CR26]\] regarding the association between *MUC5B* rs35705950 and the risk of idiopathic pulmonary fibrosis. However, only ten studies were included, and the genetic association between *MUC5B* rs35705950 and the susceptibility to other pneumonia types has not yet been investigated. Therefore, we performed an updated meta-analysis to comprehensively assess the effect of *MUC5B* rs35705950 on the risk of overall pneumonia disease based on available case-control studies as of February 2020.

Methods {#Sec2}
=======

Database search and study identification {#Sec3}
----------------------------------------

Referring to similar investigations \[[@CR27], [@CR28]\], we collected potentially relevant studies from three databases, including PubMed, EMBASE (Excerpta Medica Database), and WOS (Web of Science), on 25 February 2020. To prevent the filtering of the possible eligible studies, in the retrieval strategy, we utilized a combination of subject words \["MeSH (medical subject headings)" for PubMed and "Emtree" for EMBASE\] and free words ("Entry Terms" for PubMed, "synonyms" for EMBASE) in the retrieval strategy. No restriction on publication language or region was applied. The detailed search terms can be found in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Based on our exclusion/inclusion criteria, we then performed the study identification and eligibility assessment. The exclusion criteria were as follows: (i) meta-analysis, comment or review; (ii) mice or cell data; (iii) conference abstract or case reports; (iv) other gene or disease; (v) lack of normal controls or specific data; and (vi) not in line with HWE (Hardy-Weinberg equilibrium) principle. Only those studies with allelic or genotypic frequency data from both the pneumonia cases and negative controls were enrolled.

Evidence collection and quality appraisal {#Sec4}
-----------------------------------------

After full-text verification of each case-control study, we extracted and sorted the basic information (e.g., the first name of the author, publication date, race, variation, frequency) in Excel files. We also contacted corresponding authors by email in an attempt to retrieve any missing data of allelic or genotypic frequency. We also applied the NOS (Newcastle-Ottawa quality assessment scale) system to evaluate the study quality.

Statistical approaches {#Sec5}
----------------------

To assess the statistical heterogeneity between studies, we performed I^2^/Q statistical tests by means of the STATA software (version 12.0 Stata Corporation, USA). The DerSimonian-Laird random effects model was used for high heterogeneity \[I^2^ \> 50% or *P*~heterogeneity~ (*P* value in the heterogeneity test) \< 0.05\]; while the Mantel-Haenszel method for fixed-effect models was used for low or no heterogeneity (I^2^ \< 50% and *P*~heterogeneity~ \> 0.05). We also utilized the STATA software to conduct association tests and obtained the OR, 95% confidence interval (CI) and *P*~*association*~ (*P* value in the association test) under a total of six models to assess the association strength.

Referencing the relevant literature \[[@CR29], [@CR30]\], we also adjusted the *P* value in the association tests using the p.adjust function of the R software, version 3.6.1. *P* values adjusted for the Bonferroni and false discovery rate (FDR) were also obtained. Furthermore, we performed a false-positive report probability (FPRP) analysis to assess the probability of a true genetic relationship using the genetic analysis "gap" R package \[[@CR31], [@CR32]\] \[FPRP cutoff value = 0.2, power OR = 1.5, and prior probability levels = (0.25, 0.1, 0.01, 0.001, 0.0001, 0.00001)\].

Trial sequential analysis {#Sec6}
-------------------------

Referencing the previous studies \[[@CR33], [@CR34]\], we carried out the trial sequential analysis (TSA) test for the assessment of conclusion robustness using the TSA viewer software (<http://www.ctu.dk/tsa/>) (type I error probability = 5%, statistical test power = 80%, and relative risk reduction =20%).

Publication bias and sensitivity analyses {#Sec7}
-----------------------------------------

Additionally, we conducted a group of subgroup analyses by the factors of race, control source, and pneumonia type. We also carried out the Begg and Egger tests for analyzing the presence of publication bias, and the sensitivity analysis was conducted using one-by-one removal of each study to evaluate data stability.

Results {#Sec8}
=======

Eligible case-control study characteristics {#Sec9}
-------------------------------------------

Figure [1](#Fig1){ref-type="fig"} shows the flow diagram of selecting eligible case-control studies. Utilizing the computerized database search process, we collected a total of 234 records (PubMed 87 records, EMBASE 18 records, and WOS 158 records). We then removed 32 duplicate records, as well as 164 records due to the following exclusion criteria: meta, comment or review (*n* = 101), mice or cell (*n* = 17), conference abstract or case report (*n* = 9), other gene or disease (*n* = 37). Another 16 records were excluded due to "lack of normal control or specific data" or "not in line with HWE". Finally, a total of twenty-two articles \[[@CR8], [@CR11]--[@CR20], [@CR23], [@CR35]--[@CR44]\] were included in the quantitative synthesis. Fourteen case-control studies from ten articles \[[@CR11]--[@CR20]\] were included in the meta-analysis of *FCGR2A* rs1801274; while thirty-one case-control studies from twelve articles \[[@CR8], [@CR23], [@CR35]--[@CR44]\] were included for *MUC5B* rs35705950. Table [1](#Tab1){ref-type="table"} presents a summary of the basic information, while Additional file [1](#MOESM1){ref-type="media"}: Table S2 presents the detailed allelic and genotypic frequency data of the enrolled case-control studies. All studies were of high quality (all NOS score \> =5), as shown in Additional file [1](#MOESM1){ref-type="media"}: Table S3. Fig. 1Flow diagram of eligible case-control study selectionTable 1Basic information of the studies included in the meta-analysisFirst author, Year \[Ref.\]RaceVariationDisease typeSampleControl sourceAssaycasecontrolBougle, 2012 \[[@CR11]\]Caucasianrs1801274ICU /pneummonia1982789HBTaqmanDressen, 2018 \[[@CR35]\]Caucasianrs35705950IPF15101874HBSequencingEndeman, 2009 \[[@CR12]\]Caucasianrs1801274CAP200313PBTaqmanForthal, 2007 \[[@CR13]\]Mixedrs1801274AIDS/ pneumonia80478HBAllele-specific PCRHorimasu, 2015 \[[@CR36]\]Asianrs35705950NSIP30310PBTaqmanIPF44310PBTaqmanCaucasianrs35705950NSIP3135PBTaqmanIPF7135PBTaqmanJohnson, 2017 \[[@CR37]\]Caucasianrs35705950IIP60134NATaqmanJonsson, 2006 \[[@CR14]\]Caucasianrs1801274C2D/pneumonia30200PBAllele-specific PCR/sequencingKinder, 2007 \[[@CR15]\]Mixedrs1801274SLE/pneumonia42217HBPyrosequencingKishore, 2016 \[[@CR38]\]Caucasianrs35705950IPF^a^4196PBSequenom MassARRAYrs35705950IPF^b^3396PBSequenom MassARRAYrs35705950IPF^c^3696PBSequenom MassARRAYrs35705950IPF^d^5196PBSequenom MassARRAYLey, 2017 \[[@CR39]\]Mixedrs35705950CHP^e^123503PBTaqmanCHP^f^65503PBTaqmanIPF^e^147503PBTaqmanIPF^f^126503PBTaqmanMoens, 2006 \[[@CR16]\]Caucasianrs1801274pneumonia55100Mixedallelic discriminationNoth, 2013 \[[@CR8]\]Mixedrs35705950IPF^g^542542PBGenome-Wide Human SNP arrayIPF^h^544687PBiPLEX Gold PlatformIPF^i^324702PBiPLEX Gold PlatformSeibold, 2011 \[[@CR23]\]Mixedrs35705950IPF492322PBSequenom iPLEXFIP83322PBSequenom iPLEXSole, 2011 \[[@CR17]\]Caucasianrs1801274pneumococcal CAP3191224MixedASREDnonbacteremic CAP2341224MixedASREDbacteremic CAP851224MixedASREDStock, 2013 \[[@CR40]\]Caucasianrs35705950IPF110416PBTaqmanvan, 2016 \[[@CR41]\]Caucasianrs35705950spIPF115249PBTaqmanFIP55249PBTaqmaniNSIP43249PBTaqmanCTD-IP35249PBTaqmanWang, 2014 \[[@CR42]\]Asianrs35705950IPF1651013PBPCR-RFLP/Taqman/sequencingCTD-NSIP1911013PBPCR-RFLP/Taqman/sequencingCTD-UIP491013PBPCR-RFLP/Taqman/sequencingpneumonia1031013PBPCR-RFLP/Taqman/sequencingWei, 2014 \[[@CR43]\]Caucasianrs35705950IPF84689PBTaqmanYee, 2000 \[[@CR18]\]Mixedrs1801274bacteremic pneumonia42136HBquantitative flow cytometrynonbacteremic pneumonia28136HBquantitative flow cytometryYuan, 2003 \[[@CR19]\]Caucasianrs1801274pneumonia6320PB^\#^SSPpneumonia6358PB^%^SSPZhang, 2011 \[[@CR44]\]Caucasianrs35705950IPF^j^246166PBTaqmanIPF^k^95636PBTaqmanZuniga, 2012 \[[@CR20]\]Mixedrs1801274pneumonia9198PBTaqman*Ref.* reference, *M* major allele (A for rs1801274; G for rs35705950), *m* minor allele (G for rs1801274; T for rs35705950), *ICU* intensive care unit, *IPF* idiopathic pulmonary fibrosis, *CAP* community-acquired pneumonia, *AIDS* acquired immune deficiency syndrome, *NSIP* nonspecific interstitial pneumonia, *IIP* idiopathic interstitial pneumonia, *C2D*, homozygous C2 deficiency, *SLE* systemic lupus erythematosus, *CHP* chronic hypersensitivity pneumonitis, *FIP* familial interstitial pneumonia, *spIPF* sporadic type of idiopathic pulmonary fibrosis, *iNSIP* idiopathic non-specific interstitial pneumonia, *CTD-IP* connective tissue disease associated intersititial pneumonia, *CTD-NSIP* connective tissue diseases-nonspecific interstitial pneumonia pattern, *CTD-UIP* connective tissue diseases-usual interstitial pneumonia pattern, *HB* hospital-based, *PB* population-based, NA not available, *ASRED* allele-specific restriction enzyme digestion, *PCR* polymerase chain reaction, *SNP* single nucleotide polymorphism*, SSP* sequence specific PCR, *RFLP* restriction fragment length polymorphism*a* data of Czech Republic, *b* data of Germany, *c* data of Greece, *d* data of France,*e* data of University of California San Francisco, *f* data of University of Texas Southwestern,*g* stage one of genome-wide association study, *h* stage two of genome-wide association study,*i* stage three of genome-wide association study, *j* data of University of Pittsburgh, k, data of University of Chicago,*\#* healthy control, *%* normal random blood donors

*FCGR2A* rs1801274 {#Sec10}
------------------

As presented in Table [2](#Tab2){ref-type="table"}, the lack of high inter-study heterogeneity (I^2^ = 26.0%, *P*~heterogeneity~ = 0.182) resulted in using a fixed-effect model for the carrier G vs. A model, whereas a random-effect model was applied for the others. Upon the pooling analysis of thirteen studies (1332 cases /5428 controls) of the overall population, we failed to observe a significant difference between pneumonia cases and negative controls under the allelic G vs. A, carrier G vs. A, GG vs. AA, AG vs. AA, AG + GG vs. AA, or GG vs. AA+AG models (Table [3](#Tab3){ref-type="table"}, all *P*~association~ \> 0.05; Bonferroni-*P*~association~ \> 0.05; FDR-*P*~association~ \> 0.05). Next, we conducted a series of subgroup analyses by race or control source under the six genetic models. As shown in Table [3](#Tab3){ref-type="table"}, we observed similar negative results in all subgroups (all *P*~association~ \> 0.05, Bonferroni-*P*~association~ \> 0.05; FDR-*P*~association~ \> 0.05), except in the subgroup analysis of "HB" under the AG vs. AA model (*P*~association~ = 0.023, Bonferroni-*P*~association~ = 0.138; FDR-*P*~association~ = 0.1380). Fig. [2](#Fig2){ref-type="fig"} shows the forest plot data under the allelic model (as an example). These findings showed that *FCGR2A* rs1801274 may not be strongly associated with overall pneumonia susceptibility. Table 2Data of heterogeneity assessment and publication bias analysisGene (Variation)Genetic modelHeterogeneityFixed/RandomPublication biasI^2^*P*~*heterogeneity*~*P*~*Begg*~*P*~*Egger*~***FCGR2A*(rs1801274)**Allelic G vs. A74.3%\< 0.001Random0.7600.882Carrier G vs. A26.0%0.182Fixed0.3100.830GG vs. AA71.9%\< 0.001Random1.0000.899AG vs. AA62.3%0.001Random0.4280.337AG + GG vs. AA68.7%\< 0.001Random0.8550.872GG vs. AA+AG64.3%0.001Random0.4430.395***MUC5B*(rs35705950)**Allelic T vs. G72.4%\< 0.001Random0.6830.382Carrier T vs. G0.7%0.449Fixed0.7400.182TT vs GG0.0%0.870Fixed0.4880.070GT vs. GG59.4%\< 0.001Random0.1740.002GT + TT vs. GG63.4%\< 0.001Random0.1940.002TT vs. GG + GT0.0%0.959Fixed0.3730.477*P*~*heterogeneity*~*P* value in the heterogeneity test, *P*~*Begg*~*P* value in the Begg test, *P*~*Egger*~*P* value in the Egger testTable 3Pooling data regarding the association between *FCGR2A* rs1801274 and pneumonia riskGenetic modelSubgroupSample sizeAssociationStudyCase/controlOR (95% CI)*P*~*association*~Bonferroni-*P*~*association*~FDR-*P*~*association*~**Allelic G vs. A**Overall131332/54281.08 \[0.89,1.31\]0.4501.0000.6312Caucasian81049/43631.03 \[0.87,1.22\]0.7421.0000.8904PB5447/6891.35 \[0.88,2.08\]0.1691.0000.3015HB4192/9670.97 \[0.60,1.58\]0.9061.0000.9060**Carrier G vs. A**Overall131332/54281.05 \[0.94,1.16\]0.3781.0000.6312Caucasian81049/43631.04 \[0.92,1.16\]0.5541.0000.8904PB5447/6891.16 \[0.95,1.43\]0.1530.9180.3015HB4192/9670.93 \[0.71,1.22\]0.6031.0000.8364**GG vs. AA**Overall131332/54281.13 \[0.78,1.64\]0.5261.0000.6312Caucasian81049/43631.06 \[0.76,1.48\]0.7291.0000.8904PB5447/6891.76 \[0.74,4.19\]0.2011.0000.3015HB4192/9670.86 \[0.40,1.84\]0.6971.0000.8364**AG vs. AA**Overall131332/54280.87 \[0.65,1.16\]0.3411.0000.6312Caucasian81049/43630.94 \[0.71,1.25\]0.6841.0000.8904PB5447/6891.04 \[0.63,1.73\]0.8791.0000.8790HB4192/9670.55 \[0.32,0.92\]0.0230.1380.1380**AG + GG vs. AA**Overall131332/54280.96 \[0.72,1.30\]0.8121.0000.8120Caucasian81049/43630.98 \[0.74,1.30\]0.8991.0000.8990PB5447/6891.27 \[0.70,2.30\]0.4301.0000.5160HB4192/9670.67 \[0.42,1.09\]0.1060.6360.3180**GG vs. AA + AG**Overall141530/82171.19 \[0.93,1.52\]0.1781.0000.6312Caucasian91247/71521.05 \[0.85,1.29\]0.6621.0000.8904PB5447/6891.71 \[0.94,3.13\]0.0810.4860.3015HB5390/37561.12 \[0.67,1.87\]0.6691.0000.8364*PB* population-based, *HB* hospital-based, *OR* odds ratio, *CI* 95% confidence interval, *P*~*association*~*P* value in the association test, *Bonferroni*-*P*~association~ Bonferroni-adjusted *P* value in the association test, *FDR*-*P*~association~ false discovery rate-adjusted *P* value in the association testFig. 2Forest plot of *FCGR2A* rs1801274 under the allelic model

*MUC5B* rs35705950 {#Sec11}
------------------

For the pooling analysis of *MUC5B* rs35705950, we included a total of thirty-one studies with 5644 cases and 14,624 controls (Table [4](#Tab4){ref-type="table"}) in the overall population. The lack of high inter-study heterogeneity led to using a fixed-effect model for the carrier G vs. A model (Table [2](#Tab2){ref-type="table"}, I^2^ = 0.7%, *P*~heterogeneity~ = 0.449), TT vs. GG (I^2^ = 0.0%, *P*~heterogeneity~ = 0.870), and TT vs. GG + GT (I^2^ = 0.0%, *P*~heterogeneity~ = 0.959), but a random-effect model was used for the others. The pooling results in Table [4](#Tab4){ref-type="table"} show a significant association between *MUC5B* rs35705950 and high susceptibility to pneumonia in the overall population under the genetic models of allelic T vs. G (OR = 3.78), carrier T vs. G (OR = 3.31), TT vs. GG (OR = 13.66), GT vs. GG (OR = 4.78), GT + TT vs. GG (OR = 5.05), and TT vs. GG + GT (OR = 6.47) (all *P*~association~ \< 0.001, Bonferroni-*P*~association~ \< 0.006; FDR-*P*~association~ \< 0.0010). Subsequently, we observed similar positive correlations in the followed subgroup analyses of "Caucasian", "PB", and "IPF" under all genetic models (Table [4](#Tab4){ref-type="table"}, OR \> 3, *P*~association~ \< 0.01, Bonferroni-*P*~association~ \< 0.006; FDR-*P*~association~ \< 0.0010). In the "NSIP" subgroup, we detected positive results under the allelic (Table [4](#Tab4){ref-type="table"}, OR = 3.01), carrier (OR = 2.66), and GT + TT vs. GG (OR = 3.19) (*P*~association~ \< 0.001, Bonferroni-*P*~association~ \< 0.006; FDR-*P*~association~ \< 0.0015). In the "Asian" subgroup, we also observed a positive association between *MUC5B* rs35705950 and the high risk of pneumonia under the genetic models of allelic T vs. G (OR = 2.76), carrier T vs. G (OR = 2.47), GT vs. GG (OR = 2.78), and GT + TT vs. GG (OR = 2.78) (all *P*~association~ \< 0.001, Bonferroni-*P*~association~ \< 0.006; FDR-*P*~association~ \< 0.0010). Furthermore, based on the applicable conditions of FPRP \[[@CR31], [@CR32]\], we applied FPRP analysis for the data of the "Asian" subgroup. As shown in Additional file [1](#MOESM1){ref-type="media"}: Table S4, the observed FPRP values under the prior probability level of 0.1 were all less than 0.20, confirming notable associations. Forest plots of the subgroup analyses are presented in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"}: Figures S1-S6. The above evidence demonstrated that *MUC5B* rs35705950 is closely linked to a high susceptibility to pneumonia diseases, especially to idiopathic pulmonary fibrosis, in the Asian and Caucasian populations. Table 4Pooling data regarding the association between *MUC5B* rs35705950 and pneumonia riskGenetic modelSubgroupSample sizeAssociationStudyCase/controlOR (95% CI)*P*~*association*~Bonferroni-*P*~*association*~FDR-*P*~*association*~**Allelic T vs. G**Overall315644/14,6243.78 \[3.25,4.39\]\< 0.001\< 0.006\< 0.0010Caucasian152556/52314.23 \[3.57,5.02\]\< 0.001\< 0.006\< 0.0010Asian6582/46722.76 \[1.67,4.56\]\< 0.001\< 0.006\< 0.0010PB294074/12,6163.69 \[3.15,4.32\]\< 0.001\< 0.006\< 0.0010IPF194776/90314.03 \[3.38,4.81\]\< 0.001\< 0.006\< 0.0010NSIP4295/16073.01 \[1.79,5.08\]\< 0.001\< 0.006\< 0.0015**Carrier T vs. G**Overall213138/99033.31 \[3.01,3.65\]\< 0.001\< 0.006\< 0.0010Caucasian152556/52313.35 \[3.03,3.70\]\< 0.001\< 0.006\< 0.0010Asian6582/46722.47 \[1.52,4.02\]\< 0.001\< 0.006\< 0.0010PB201628/80293.10 \[2.69,3.57\]\< 0.001\< 0.006\< 0.0010IPF132601/57723.43 \[3.10,3.80\]\< 0.001\< 0.006\< 0.0010NSIP4295/16072.66 \[1.66,4.26\]\< 0.001\< 0.006\< 0.0015**TT vs. GG**Overall152556/523113.66 \[10.01,18.63\]\< 0.001\< 0.006\< 0.0010Caucasian152556/523112.66 \[10.01,18.63\]\< 0.001\< 0.006\< 0.0010PB141046/335710.45 \[6.66,16.37\]\< 0.001\< 0.006\< 0.0010IPF112392/444913.87 \[10.08,19.09\]\< 0.001\< 0.006\< 0.0010NSIP274/28412.29 \[1.61,93.86\]0.016\< 0.096\< 0.0015**GT vs. GG**Overall213138/99034.78 \[3.76,6.06\]\< 0.001\< 0.006\< 0.0010Caucasian152556/52315.33 \[4.20,6.77\]\< 0.001\< 0.006\< 0.0010Asian6582/46722.78 \[1.66,4.65\]\< 0.001\< 0.006\< 0.0010PB201628/80294.56 \[3.60,5.78\]\< 0.001\< 0.006\< 0.0010IPF132601/57726.35 \[5.49,7.34\]\< 0.001\< 0.006\< 0.0010NSIP4295/16072.91 \[1.72,4.92\]0.0100.0600.0120**GT + TT vs. GG**Overall213138/99035.05 \[3.96,6.45\]\< 0.001\< 0.006\< 0.0010Caucasian152556/52315.70 \[4.46,7.27\]\< 0.001\< 0.006\< 0.0010Asian6582/46722.78 \[1.66,4.65\]\< 0.001\< 0.006\< 0.0010PB201628/80294.82 \[3.78,6.16\]\< 0.001\< 0.006\< 0.0010IPF132601/57726.49 \[5.48,7.68\]\< 0.001\< 0.006\< 0.0010NSIP4295/16073.19 \[1.75,5.83\]\< 0.001\< 0.006\< 0.0015**TT vs. GG + GT**Overall152556/52316.47 \[4.77,8.77\]\< 0.001\< 0.006\< 0.0010Caucasian152556/52316.47 \[4.77,8.77\]\< 0.001\< 0.006\< 0.0010PB141046/33575.76 \[3.76,8.85\]\< 0.001\< 0.006\< 0.0010IPF112392/44496.45 \[4.72,8.81\]\< 0.001\< 0.006\< 0.0010NSIP274/2848.41 \[1.11,63.80\]0.0400.2400.0400*PB* population-based, *IPF* idiopathic pulmonary fibrosis, *NSIP* nonspecific interstitial pneumonia, *OR* odds ratio, *CI* 95% confidence interval, *P*~*association*~*P* value in the association test, *Bonferroni*-*P*~association~ Bonferroni-adjusted *P* value in the association test, *FDR*-*P*~association~ false discovery rate adjusted-*P* value in the association testFig. 3Subgroup analysis of "race" for *MUC5B* rs35705950 under the allelic modelFig. 4Subgroup analysis of "pneumonia type" for *MUC5B* rs35705950 under the allelic model

Publication bias {#Sec12}
----------------

As shown in Table [2](#Tab2){ref-type="table"}, we did not observe a large publication bias among the comparisons, as evidenced by *P*~*Begg*~ \> 0.05 and *P*~*Egger*~ \> 0.05 for all models except the Egger test under GT vs. GG (*P*~*Egger*~ = 0.002) and GT + TT vs. GG (*P*~*Egger*~ = 0.002) for *MUC5B* rs35705950. Fig. [5](#Fig5){ref-type="fig"}a and Additional file [2](#MOESM2){ref-type="media"}: Figure S7a display the Begg test plot under the allelic model (as an example). Fig. 5Sensitivity analysis and Begg test plot for *MUC5B* rs35705950 under the allelic model. **a** Sensitivity analysis data; **b** Begg test

Sensitivity and TSA data {#Sec13}
------------------------

We observed relatively stable pooling data in the sensitivity analyses of *FCGR2A* rs1801274 (e.g., Additional file [2](#MOESM2){ref-type="media"}: Figure S7b for the allelic model). However, our TSA test data (Figure [S8](#MOESM2){ref-type="media"}) showed that the cumulative Z-curve did not totally reach the conventional boundary and required information size, suggesting the requirement for a larger sample size to confirm the negative association between *FCGR2A* rs1801274 and pneumonia risk.

With regards to *MUC5B* rs35705950, we found that the cumulative Z-curve of GT + TT vs. GG model can cross the TSA monitoring boundary despite not reaching the required information size in the overall population (Additional file [2](#MOESM2){ref-type="media"}: Figure S9), Caucasian population (Additional file [2](#MOESM2){ref-type="media"}: Figure S10), and Asian population (Additional file [2](#MOESM2){ref-type="media"}: Figure S11), indicating the robustness of the conclusions. Furthermore, we also observed the relatively stable or credible outcomes for the *MUC5B* rs35705950 through the sensitivity analyses (e.g., Fig. [5](#Fig5){ref-type="fig"}b for the allelic model).

Discussion {#Sec14}
==========

The inconclusive result of the genetic influence of *FCGR2A* rs1801274 on the susceptibility to clinical pneumonia has been observed in previous studies. For example, a negative effect of *FCGR2A* rs1801274 was detected for the development of pneumonia in systemic lupus erythematosus patients \[[@CR15]\]; additionally, *FCGR2A* rs1801274 was not found to increase the risk of invasive pneumococcal disease in Belgium \[[@CR16]\]. Although *FCGR2A* rs1801274 was not identified in any genome-wide association study (GWAS) of pneumonia \[[@CR8], [@CR22]\], we observed a positive association between *FCGR2A* rs1801274 and the risk of pneumonia. *FCGR2A* rs1801274 was reported to be significantly associated with the risk of severe pneumonia in A/H1N1 influenza infection \[[@CR20]\], bacteremic pneumococcal pneumonia infection \[[@CR18]\], and the severity of community-acquired pneumonia \[[@CR12]\]. Here, for the first time, we carried out a meta-analysis and TSA test to comprehensively evaluate the genetic influence of *FCGR2A* rs1801274 in the susceptibility to clinical pneumonia. Upon pooling a total of 1332 cases and 5428 controls from thirteen studies, no strong evidence was found to support a significant association between *FCGR2A* rs1801274 and overall pneumonia risk.

In 2013, Borie, R. et al. included four case-control studies from three articles \[[@CR23], [@CR24], [@CR44]\] to perform a meta-analysis of the association between *MUC5B* rs35705950 and idiopathic pulmonary fibrosis risk \[[@CR24]\]. A total of nine case-control studies from seven articles \[[@CR8], [@CR23], [@CR24], [@CR36], [@CR40], [@CR42], [@CR45]\] were included in another meta-analysis by Zhu, Q. Q. in 2015 \[[@CR26]\]; while twelve case-control studies from eight articles \[[@CR8], [@CR23], [@CR24], [@CR36], [@CR40], [@CR42], [@CR43], [@CR46]\] were included in an updated meta-analysis by Lee, M. G. et al., 2015 \[[@CR25]\]. Given the differences in study selection, basic information extraction, pooling strategies and data description, we carried out a quantitative synthesis to assess the effect of *MUC5B* rs35705950 on the risk of pneumonia diseases, including idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.

In the present study, we performed the extensive retrieval of three databases (as of 25 February 2020) to capture potential publications for inclusion in a series of pooling analyses. Based on our strict screening strategy, we included a total of 5644 cases and 14,624 controls across thirty-one studies in the overall meta-analysis, followed by subgroup analyses according to the factors of race, control source and pneumonia type. A total of six genetic models, namely, allelic, carrier, homozygotic, heterozygotic, dominant and recessive, were applied. We excluded the studies based on the strict requirements of the HWE principle. Our pooling data suggest that *MUC5B* rs35705950 is closely associated with an increased risk of pneumonia diseases, especially idiopathic pulmonary fibrosis, in both Asians and Caucasians. The positive genetic relationship between *MUC5B* rs35705950 and high susceptibility to idiopathic pulmonary fibrosis is consistent with the results of previous meta-analyses \[[@CR24]--[@CR26]\] and GWAS evidence \[[@CR8], [@CR22]\]. When comparing the OR value under different genetic models, the TT genotype carriers were found to be more susceptible to pneumonia disease than the GT genotype carriers. It is possible that the "T" allele of *MUC5B* rs35705950 confers an enhanced susceptibility to pneumonia patients in a dose-dependent manner.

Our study has several advantages over other studies. First, none of the included case-control studies were of low quality based on the assessment analysis of the NOS system. Second, we excluded case-control studies in which the genotypic distribution in the control group did not conform to the HWE principle. Third, we found no obvious evidence of a large publication bias, according to the Begg and Egger analyses. Fourth, we observed the stability of the pooling data when applying our leave-one-out sensitivity analysis, along with the FPRP and TSA analyses. Our study enables readers to understand the current research status of pneumonia-related *MUC5B* rs35705950 in different populations, as well as the pooling evidence based on the currently available data.

However, some disadvantages of our study may affect our statistical power. There was high inter-study heterogeneity in some comparisons. Despite thirteen case-control studies being included in the overall pooling analysis for *FCGR2A* rs1801274, certain subgroups contained small sample sizes. For example, very limited case-control studies in the subgroup analysis of "specific pneumonia type" deterred us from performing the relative analysis. No cases in the homogenous Asian population were enrolled for pooling analysis. Although we observed a negative result in the pooling analysis based on the presently available data, our new TSA test for *FCGR2A* rs1801274 indicated the necessity for a larger sample size to confirm the negative association between *FCGR2A* rs1801274 and pneumonia risk both the Caucasian and Asian populations.

We observed a positive association between *MUC5B* rs35705950 and the overall risk of pneumonia in the Asian population. We also performed FPRP and TSA tests to confirm this relationship. However, there were only five case-control studies, and we could not perform further pooling analysis based on the different phenotypes due to the limited available data. Likewise, only four case-control studies were included in the subgroup analysis of "NSIP". We failed to detect a genetic influence of *MCU5B* rs35705950 on the risk of other pneumonia types, such as idiopathic interstitial pneumonia, chronic hypersensitivity pneumonitis, and familial interstitial pneumonia.

When more case-control studies become available, it would be meaningful to take additional factors into consideration, such as gender, age, exposure, and drinking/smoking status. As mentioned above, *FCGR2A* rs1801274 and *MUC5B* rs35705950 were selected due to the research status of pneumonia-related variations and the novelty of the data analysis. Thus, there is no obvious correlation between the two. Nevertheless, it is still meaningful to analyze the combined impact of different variants of other genes \[e.g., rs2736100 in *TERT* (telomerase reverse transcriptase)\] on the susceptibility to the different types of pneumonia in different populations when the data become available.

Conclusion {#Sec15}
==========

Our findings revealed that *MUC5B* rs35705950 is strongly linked to an increased risk of pneumonia diseases in the Asian and Caucasian populations. Owing to data limitations, more available evidence is required to further clarify the genetic relationship between *FCGR2A* rs1801274 and pneumonia susceptibility.
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FCGR2A

:   Fc fragment of IgG receptor IIa

MUC5B

:   Mucin 5B, oligomeric mucus/gel-forming

AIDS

:   Immune deficiency syndrome

IPF

:   Idiopathic pulmonary fibrosis

NSIP

:   Nonspecific interstitial pneumonia

IIP

:   Idiopathic interstitial pneumonia

PRISMA

:   Preferred reporting items for systematic reviews and meta-analyses

EMBASE

:   Excerpta Medica Database

WOS

:   Web of Science

MeSH

:   Medical subject headings

HWE

:   Hardy-Weinberg equilibrium

NOS

:   Newcastle-Ottawa quality assessment scale

CI

:   Confidence interval

FDR

:   False discovery rate

FPRP

:   False-positive report probability

TSA

:   Trial sequential analysis

GWAS

:   Genome-wide association study

TERT

:   Telomerase reverse transcriptase
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